Table 1.
Clinimetrics.
| Median | IQR | |
|---|---|---|
| Number of participants | 16 | |
| Age (years) | 69 | 13 |
| Gender (% male) | 81 | |
| Disease duration (years) | 10 | 9 |
| Years since FOG | 4 | 9 |
| LEDD (mg/day) | 1220 | 776 |
| UPDRS-part III | 38 | 17 |
| Hoehn and Yahr (II/III) | 2 | 1 |
| MMSE | 29 | 2 |
| NFOGQ | 18 | 7 |
| FAB | 17 | 2 |
The median and interquartile range (IQR) quartiles are given, unless stated otherwise. FOG, freezing of gait; LEDD, levodopa equivalent daily dose; UPDRS-part III, Unified Parkinson's Disease Rating Scale part III; MMSE, mini-mental state examination (range 0–30); NFOGQ, New Freezing of Gait Questionnaire (range 0–28); FAB, Frontal Assessment Battery (range 0–18). All questionnaires were rated while participants were at the end of a dopaminergic medication cycle (“end-of-dose”).